NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Price Target & More

$114.05 +8.01 (+7.55 %)
(As of 04/26/2018 09:24 AM ET)
Previous Close$106.04
Today's Range$114.05 - $114.05
52-Week Range$96.18 - $149.34
Volume47,171 shs
Average Volume2.14 million shs
Market Capitalization$23.68 billion
P/E Ratio21.01
Dividend YieldN/A
Beta1.13

About Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals logoAlexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596

Debt

Debt-to-Equity Ratio0.34%
Current Ratio3.10%
Quick Ratio2.62%

Price-To-Earnings

Trailing P/E Ratio21.01
Forward P/E Ratio18.64
P/E Growth0.95

Sales & Book Value

Annual Sales$3.55 billion
Price / Sales7.14
Cash Flow$8.6011 per share
Price / Cash13.26
Book Value$39.81 per share
Price / Book2.86

Profitability

EPS (Most Recent Fiscal Year)$5.16
Net Income$443.30 million
Net Margins12.48%
Return on Equity12.94%
Return on Assets8.50%

Miscellaneous

Employees2,525
Outstanding Shares222,360,000

How to Become a New Pot Stock Millionaire

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How will Alexion Pharmaceuticals' stock buyback program work?

Alexion Pharmaceuticals announced that its board has approved a share buyback program on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 3.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals (NASDAQ:ALXN) announced its quarterly earnings results on Wednesday, April, 25th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.50 by $0.18. The biopharmaceutical company earned $930.90 million during the quarter, compared to the consensus estimate of $920.50 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The firm's quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.38 EPS. View Alexion Pharmaceuticals' Earnings History.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals updated its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $6.75-6.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.82. The company issued revenue guidance of $3.925-3.985 billion, compared to the consensus revenue estimate of $3.98 billion.

What price target have analysts set for ALXN?

21 equities research analysts have issued 12 month target prices for Alexion Pharmaceuticals' shares. Their predictions range from $120.00 to $180.00. On average, they expect Alexion Pharmaceuticals' share price to reach $156.5238 in the next year. View Analyst Ratings for Alexion Pharmaceuticals.

What are Wall Street analysts saying about Alexion Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis is likely to boost sales further. The prospects of ALXN1210 looks good too and a tentative approval will boost the top-line. Alexion is looking to diversify its portfolio and reduce its dependence on its blockbuster drug Soliris. The recently announced Wilson deal will strengthen Alexion’s rare disease pipeline with a late-stage candidate, WTX101 which is currently in phase III for the treatment of Wilson disease, a rare genetic disorder. Earlier, Alexion has de-prioritized a few clinical programs and terminated partnerships with Moderna Therapeutics among others. Shares of the company have performed better than the industry in the last three months. However, the company relies heavily on Soliris for growth and sales of the same will be impacted by ramp-up of ALXN1210 trials. Pricing will also hit sales." (4/19/2018)
  • 2. JPMorgan Chase analysts commented, "Additionally, post a series of physician calls in the space, while competitor complement players will have updates in the next 6-18 months, we believe the '1210 profile is already clinically compelling and the burden is on competitors to produce meaningful data," (9/5/2017)

Who are some of Alexion Pharmaceuticals' key competitors?

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 55)
  • Mr. Paul J. Clancy, Exec. VP & CFO (Age 56)
  • Ms. Julie O'Neill MBA, Exec. VP of Global Operations (Age 62)
  • Mr. John B. Moriarty Jr., Former Exec. VP & Gen. Counsel (Age 50)
  • Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 49)

Has Alexion Pharmaceuticals been receiving favorable news coverage?

Press coverage about ALXN stock has trended positive on Thursday, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a daily sentiment score of 0.27 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.74 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $114.00.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $23.68 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596.


MarketBeat Community Rating for Alexion Pharmaceuticals (ALXN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  916 (Vote Outperform)
Underperform Votes:  486 (Vote Underperform)
Total Votes:  1,402
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alexion Pharmaceuticals (NASDAQ:ALXN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Alexion Pharmaceuticals in the last 12 months. Their average twelve-month price target is $156.5238, suggesting that the stock has a possible upside of 37.24%. The high price target for ALXN is $180.00 and the low price target for ALXN is $120.00. There are currently 1 hold rating and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.952.952.902.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
19 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $156.5238$155.7273$153.55$154.8636
Price Target Upside: 37.24% upside19.16% upside25.74% upside14.54% upside

Alexion Pharmaceuticals (NASDAQ:ALXN) Consensus Price Target History

Price Target History for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/23/2018Raymond JamesReiterated RatingBuyLowView Rating Details
4/12/2018NomuraBoost Price TargetBuy$165.00LowView Rating Details
3/16/2018Credit Suisse GroupReiterated RatingOutperform -> Outperform$147.00 -> $149.00HighView Rating Details
3/15/2018Robert W. BairdSet Price TargetBuy$160.00LowView Rating Details
3/15/2018Deutsche BankSet Price TargetBuy$161.00HighView Rating Details
3/9/2018CowenReiterated RatingBuy$163.00LowView Rating Details
2/12/2018SunTrust BanksSet Price TargetBuy$172.00MediumView Rating Details
2/9/2018BMO Capital MarketsBoost Price TargetOutperform -> Outperform$177.00 -> $180.00LowView Rating Details
2/9/2018Stifel NicolausReiterated RatingBuy$151.00MediumView Rating Details
2/9/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$148.00 -> $151.00LowView Rating Details
2/9/2018Leerink SwannLower Price TargetOutperform -> Outperform$166.00 -> $153.00LowView Rating Details
2/9/2018CitigroupLower Price TargetBuy -> Buy$173.00 -> $170.00LowView Rating Details
2/5/2018Evercore ISIUpgradeIn-Line -> OutperformHighView Rating Details
1/4/2018UBSDowngradeStrong-Buy -> OutperformMediumView Rating Details
10/24/2017Royal Bank of CanadaBoost Price Target$166.00N/AView Rating Details
10/23/2017Piper JaffrayReiterated RatingOverweight -> Overweight$170.00N/AView Rating Details
9/5/2017JPMorgan ChaseUpgradeNeutral -> Overweight$163.00 -> $175.00MediumView Rating Details
7/28/2017OppenheimerUpgradeMarket Perform -> Outperform$175.00HighView Rating Details
6/9/2017Goldman SachsReiterated RatingBuy$142.00LowView Rating Details
6/8/2017Jefferies GroupSet Price TargetHold$120.00MediumView Rating Details
5/24/2017BarclaysReiterated RatingOverweight$155.00HighView Rating Details
3/30/2017InstinetReiterated RatingBuy$148.00LowView Rating Details
12/13/2016WedbushReiterated RatingNeutral$135.00N/AView Rating Details
11/30/2016FBR & CoReiterated RatingMarket Perform$130.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$221.00N/AView Rating Details
6/6/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Alexion Pharmaceuticals (NASDAQ:ALXN) Earnings History and Estimates Chart

Earnings by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$1.25$1.37$1.31

Alexion Pharmaceuticals (NASDAQ ALXN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018        
4/25/2018Q1 2018$1.50$1.68$920.50 million$930.90 millionViewN/AView Earnings Details
2/8/2018Q4 2017$1.09$1.48$880.38 million$909.70 millionViewN/AView Earnings Details
10/26/2017Q3 2017$1.32$1.44$864.34 million$859.00 millionViewN/AView Earnings Details
7/27/2017Q2 2017$1.08$1.56$846.15 million$912.00 millionViewN/AView Earnings Details
4/27/2017Q1 2017$1.05$1.38$826.63 million$870.00 millionViewN/AView Earnings Details
2/16/2017Q416$1.25$1.26$840.69 million$831.00 millionViewN/AView Earnings Details
10/27/2016Q316$1.04$1.23$787.07 million$799.00 millionViewListenView Earnings Details
7/28/2016Q216$0.91$1.13$743.18 million$753.00 millionViewListenView Earnings Details
4/28/2016Q116$1.13$1.11$710.98 million$701.00 millionViewListenView Earnings Details
2/3/2016Q415$1.10$1.13$703.42 million$701.00 millionViewN/AView Earnings Details
10/29/2015Q315$1.01$1.16$668.33 million$666.60 millionViewListenView Earnings Details
7/30/2015Q215$1.31$1.44$628.03 million$636.00 millionViewListenView Earnings Details
4/23/2015Q115$1.18$1.28$594.40 million$600.30 millionViewN/AView Earnings Details
1/29/2015Q414$1.17$1.13$589.85 million$599.00 millionViewListenView Earnings Details
10/23/2014Q314$1.05$1.27$541.93 million$555.10 millionViewListenView Earnings Details
7/24/2014Q214$0.99$0.99$509.54 million$512.50 millionViewListenView Earnings Details
4/24/2014Q114$1.26$1.53$560.22 million$566.60 millionViewListenView Earnings Details
1/30/2014Q413$0.83$0.87$430.08 million$441.90 millionViewListenView Earnings Details
10/24/2013Q313$0.79$0.83$395.10 million$400.40 millionViewListenView Earnings Details
7/25/2013Q2 2013$0.68$0.73$364.80 million$370.10 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.61$0.65$336.56 million$338.90 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.52$0.60$316.49 million$320.50 millionViewListenView Earnings Details
10/24/2012$0.47$0.60ViewN/AView Earnings Details
7/25/2012$0.36$0.47ViewN/AView Earnings Details
4/24/2012$0.38$0.45ViewN/AView Earnings Details
2/9/2012$0.33$0.41ViewN/AView Earnings Details
10/20/2011$0.28$0.37ViewN/AView Earnings Details
7/21/2011$0.26$0.29ViewN/AView Earnings Details
4/21/2011$0.51$0.59ViewN/AView Earnings Details
2/10/2011$0.50$0.51ViewN/AView Earnings Details
10/21/2010Q3 2010$0.19$0.15ViewN/AView Earnings Details
7/22/2010Q2 2010$0.15$0.16ViewN/AView Earnings Details
4/22/2010Q1 2010$0.12$0.11ViewN/AView Earnings Details
2/11/2010Q4 2009$0.12$0.12ViewN/AView Earnings Details
10/22/2009Q3 2009$0.11$0.15ViewN/AView Earnings Details
7/23/2009Q2 2009$0.09$0.11ViewN/AView Earnings Details
4/23/2009Q1 2009$0.07$0.08ViewN/AView Earnings Details
2/12/2009Q4 2008$0.05$0.08ViewN/AView Earnings Details
10/23/2008Q3 2008$0.02$0.11ViewN/AView Earnings Details
7/29/2008Q2 2008($0.04)$0.02ViewN/AView Earnings Details
4/30/2008Q1 2008($0.11)($0.03)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.12)($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Alexion Pharmaceuticals (NASDAQ:ALXN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.35%
Institutional Ownership Percentage: 94.76%
Insider Trading History for Alexion Pharmaceuticals (NASDAQ:ALXN)
Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ ALXN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/28/2018Heidi L WagnerSVPSell698$119.35$83,306.30View SEC Filing  
2/28/2018Julie O'neillEVPSell1,625$119.83$194,723.75View SEC Filing  
2/8/2018Heidi L WagnerSVPSell1,774$116.31$206,333.9447,212View SEC Filing  
2/8/2018John B MoriartyEVPSell3,363$115.70$389,099.1071,400View SEC Filing  
2/8/2018Ludwig HantsonCEOSell13,245$116.31$1,540,525.95131,425View SEC Filing  
2/8/2018Paul J ClancyCFOSell6,079$116.31$707,048.4995,093View SEC Filing  
2/5/2018Heidi L WagnerSVPSell655$117.26$76,805.3032,635View SEC Filing  
2/5/2018John B MoriartyEVPSell1,261$117.26$147,864.8620,210View SEC Filing  
1/2/2018Ludwig HantsonCEOSell2,553$121.63$310,521.3936,172View SEC Filing  
10/2/2017Heidi L WagnerSVPSell120$140.00$16,800.00View SEC Filing  
9/5/2017Ann M VenemanDirectorSell835$145.81$121,751.355,480View SEC Filing  
9/5/2017Julie O'neillEVPSell4,375$145.44$636,300.0026,092View SEC Filing  
8/28/2017Julie O'neillEVPSell11,160$140.00$1,562,400.0026,704View SEC Filing  
7/31/2017Ann M VenemanDirectorSell700$137.74$96,418.006,315View SEC Filing  
6/15/2017Bros. Advisors Lp BakerDirectorBuy660,779$117.33$77,529,200.07View SEC Filing  
6/14/2017Bros. Advisors Lp BakerDirectorBuy1,348,955$116.32$156,910,445.60View SEC Filing  
6/14/2017Ludwig HantsonCEOBuy10,000$116.72$1,167,200.0038,725View SEC Filing  
3/1/2017Clare CarmichaelEVPSell2,179$131.66$286,887.1433,980View SEC Filing  
3/1/2017Heidi L WagnerSVPSell994$131.65$130,860.1029,646View SEC Filing  
3/1/2017Leonard BellDirectorSell3,978$131.96$524,936.88391,910View SEC Filing  
2/28/2017Carsten ThielEVPSell125$74.52$9,315.0030,197View SEC Filing  
2/28/2017Edward MillerSVPSell590$131.48$77,573.2015,214View SEC Filing  
2/28/2017Leonard BellDirectorSell2,738$131.71$360,621.98391,910View SEC Filing  
2/27/2017Edward MillerSVPSell260$131.20$34,112.0015,214View SEC Filing  
2/27/2017John B MoriartyEVPSell612$131.20$80,294.4045,864View SEC Filing  
2/9/2017John B MoriartyEVPSell167$126.84$21,182.2846,476View SEC Filing  
2/9/2017Leonard BellDirectorSell246$126.84$31,202.64394,648View SEC Filing  
2/7/2017Heidi L WagnerSVPSell1,932$125.97$243,374.0430,241View SEC Filing  
2/7/2017John B MoriartyEVPSell3,538$125.79$445,045.0246,801View SEC Filing  
2/7/2017Leonard BellDirectorSell8,725$125.97$1,099,088.25395,979View SEC Filing  
1/10/2017Leonard BellDirectorSell100$144.99$14,499.00403,719View SEC Filing  
1/9/2017Leonard BellDirectorSell40,065$138.48$5,548,201.20438,497View SEC Filing  
1/5/2017Alvin S ParvenDirectorSell22,659$138.35$3,134,872.6514,305View SEC Filing  
12/12/2016John B MoriartyEVPSell1,044$118.61$123,828.8450,181View SEC Filing  
12/9/2016Carsten ThielEVPSell2,308$130.00$300,040.0030,433View SEC Filing  
11/14/2016Heidi L WagnerSVPSell59$115.10$6,790.9031,936View SEC Filing  
11/4/2016Leonard BellDirectorSell37,317$140.38$5,238,560.46440,936View SEC Filing  
10/31/2016Leonard BellDirectorSell1,300$135.28$175,864.00406,589View SEC Filing  
10/14/2016Carsten ThielEVPSell4,584$120.28$551,363.5232,741View SEC Filing  
10/3/2016Carsten ThielEVPSell29$122.41$3,549.8937,325View SEC Filing  
10/3/2016Heidi L WagnerSVPSell120$122.41$14,689.2031,995View SEC Filing  
9/13/2016Carsten ThielEVPSell3,225$128.67$414,960.7540,354View SEC Filing  
9/9/2016Edward MillerSVPSell367$128.32$47,093.4416,519View SEC Filing  
9/6/2016Carsten ThielEVPSell1,000$125.94$125,940.0040,579View SEC Filing  
9/2/2016Julie O'neillEVPSell650$126.29$82,088.5035,384View SEC Filing  
8/30/2016Clare CarmichaelEVPSell1,000$127.76$127,760.0038,577View SEC Filing  
8/22/2016Alvin S ParvenDirectorSell15,000$136.53$2,047,950.006,373View SEC Filing  
8/15/2016Alvin S ParvenDirectorSell700$135.51$94,857.006,373View SEC Filing  
8/8/2016Clare CarmichaelEVPSell165$137.14$22,628.1039,577View SEC Filing  
8/8/2016David HallalCEOSell332$137.14$45,530.48189,266View SEC Filing  
8/8/2016Heidi L WagnerSVPSell222$137.14$30,445.0832,115View SEC Filing  
8/8/2016Leonard BellDirectorSell1,010$137.14$138,511.40405,289View SEC Filing  
8/8/2016Vikas SinhaCFOSell277$137.14$37,987.78178,463View SEC Filing  
6/13/2016John B MoriartyEVPSell918$135.72$124,590.9651,360View SEC Filing  
5/16/2016Martin MackayEVPSell4,097$139.20$570,302.4042,706View SEC Filing  
5/13/2016Heidi L WagnerSVPSell53$138.65$7,348.4532,337View SEC Filing  
4/1/2016David HallalCEOSell1,414$135.88$192,134.32189,632View SEC Filing  
2/29/2016Clare CarmichaelEVPSell1,312$138.91$182,249.9241,054View SEC Filing  
2/29/2016David HallalCEOSell2,014$138.93$279,805.02193,026View SEC Filing  
2/29/2016Edward MillerSVPSell329$138.91$45,701.3917,215View SEC Filing  
2/29/2016Leonard BellDirectorSell3,995$138.92$554,985.40742,222View SEC Filing  
2/29/2016Vikas SinhaCFOSell1,122$138.91$155,857.02179,862View SEC Filing  
2/8/2016David HallalCEOSell11,297$140.50$1,587,228.50173,026View SEC Filing  
2/8/2016Heidi L. WagnerSVPSell2,108$140.93$297,080.4429,937View SEC Filing  
2/8/2016Julie O'neillEVPSell2,858$141.83$405,350.1430,348View SEC Filing  
2/8/2016Leonard BellDirectorSell15,872$139.58$2,215,413.76746,192View SEC Filing  
2/8/2016Vikas SinhaCFOSell6,547$140.04$916,841.88171,862View SEC Filing  
2/5/2016Edward MillerSVPSell1,051$143.02$150,314.0214,215View SEC Filing  
12/29/2015Leonard BellDirectorSell35,000$190.66$6,673,100.00749,259View SEC Filing  
12/17/2015Leonard BellDirectorSell70,000$187.69$13,138,300.00749,259View SEC Filing  
12/11/2015Ann M VenemanDirectorSell895$187.48$167,794.603,252View SEC Filing  
12/11/2015John B. MoriartyEVPSell943$182.73$172,314.3941,340View SEC Filing  
12/8/2015Leonard BellDirectorSell70,000$188.20$13,174,000.00849,088View SEC Filing  
12/8/2015Saqib IslamEVPSell950$190.00$180,500.0036,385View SEC Filing  
11/25/2015Leonard BellDirectorSell35,000$181.89$6,366,150.00919,088View SEC Filing  
10/26/2015Saqib IslamEVPSell1,558$168.44$262,429.5238,310View SEC Filing  
9/9/2015Leonard BellDirectorSell1,050$180.10$189,105.00919,088View SEC Filing  
6/18/2015Leonard BellDirectorSell27,835$179.63$5,000,001.05View SEC Filing  
3/19/2015Leonard BellCEOSell15,952$188.07$3,000,092.64View SEC Filing  
3/2/2015Julie O'neillEVPSell11,665$101.49$1,183,880.85View SEC Filing  
3/2/2015Leonard BellCEOSell1,230$180.34$221,818.20View SEC Filing  
2/10/2015Clare CarmichaelEVPSell1,490$171.15$255,013.50View SEC Filing  
2/10/2015David HallalCOOSell1,980$171.15$338,877.00View SEC Filing  
2/10/2015Leonard BellCEOSell5,740$171.15$982,401.00View SEC Filing  
2/10/2015Vikas SinhaCFOSell1,985$171.15$339,732.75View SEC Filing  
2/9/2015Clare CarmichaelEVPSell1,665$173.75$289,293.75View SEC Filing  
2/9/2015David HallalCOOSell2,920$173.93$507,875.60View SEC Filing  
2/9/2015Leonard BellCEOSell8,660$173.98$1,506,666.80View SEC Filing  
2/9/2015Vikas SinhaCFOSell2,703$174.18$470,808.54View SEC Filing  
2/4/2015David HallalCOOSell1,373$174.18$239,149.14View SEC Filing  
2/4/2015Leonard BellCEOSell5,223$174.29$910,316.67View SEC Filing  
2/4/2015Vikas SinhaCFOSell1,571$174.19$273,652.49View SEC Filing  
12/18/2014David HallalCOOSell5,494$182.03$1,000,072.82View SEC Filing  
12/18/2014Leonard BellCEOSell30,415$179.73$5,466,487.95View SEC Filing  
12/18/2014Vikas SinhaCFOSell5,493$182.08$1,000,165.44View SEC Filing  
12/9/2014Leonard BellCEOSell133,320$198.26$26,432,023.20View SEC Filing  
12/4/2014Clare CarmichaelSVPSell10,000$196.25$1,962,500.00View SEC Filing  
12/4/2014William R KellerDirectorSell5,000$196.25$981,250.00View SEC Filing  
12/3/2014Vikas SinhaCFOSell75,000$198.96$14,922,000.00View SEC Filing  
11/3/2014David HallalCOOSell30,000$190.01$5,700,300.00View SEC Filing  
11/3/2014Martin MackayEVPSell9,375$191.52$1,795,500.00View SEC Filing  
11/3/2014Saqib IslamSVPSell28,125$190.50$5,357,812.50View SEC Filing  
11/3/2014Vikas SinhaCFOSell49,307$192.63$9,498,007.41View SEC Filing  
10/27/2014John B MoriartySVPSell10,000$189.49$1,894,900.00View SEC Filing  
10/27/2014Stephen P SquintoEVPSell5,910$188.58$1,114,507.80View SEC Filing  
10/6/2014John B MoriartySVPSell10,000$179.00$1,790,000.00View SEC Filing  
10/3/2014Stephen P SquintoEVPSell10,025$172.41$1,728,410.25View SEC Filing  
9/26/2014Leonard BellCEOSell60,000$165.12$9,907,200.00View SEC Filing  
9/24/2014Stephen P SquintoEVPSell76$159.50$12,122.00View SEC Filing  
9/18/2014Leonard BellCEOSell44,435$160.60$7,136,261.00View SEC Filing  
9/10/2014Leonard BellCEOSell12,199$165.38$2,017,470.62View SEC Filing  
9/8/2014Leonard BellCEOSell197,801$165.32$32,700,461.32View SEC Filing  
8/27/2014Leonard BellCEOSell5,912$169.17$1,000,133.04View SEC Filing  
8/25/2014Andreas RummeltDirectorSell5,052$170.53$861,517.56View SEC Filing  
8/15/2014Leonard BellCEOSell70,000$167.99$11,759,300.00View SEC Filing  
8/13/2014Leonard BellCEOSell105,000$160.71$16,874,550.00View SEC Filing  
8/12/2014Leonard BellCEOSell80,458$160.16$12,886,153.28View SEC Filing  
8/4/2014David HallalEVPSell1,349$158.00$213,142.00View SEC Filing  
8/4/2014Leonard BellCEOSell5,145$157.88$812,292.60View SEC Filing  
8/4/2014Vikas SinhaCFOSell1,525$157.82$240,675.50View SEC Filing  
7/30/2014Leonard BellCEOSell127,289$162.93$20,739,196.77View SEC Filing  
7/29/2014Leonard BellCEOSell1,200$164.93$197,916.00View SEC Filing  
7/28/2014Leonard BellCEOSell105,600$162.38$17,147,328.00View SEC Filing  
6/20/2014Leonard BellCEOSell90,280$163.60$14,769,808.00View SEC Filing  
6/12/2014Martin MackayEVPSell25,000$166.42$4,160,500.00View SEC Filing  
6/5/2014William R KellerDirectorSell3,425$170.00$582,250.00View SEC Filing  
5/27/2014Leonard BellCEOSell70,000$166.16$11,631,200.00View SEC Filing  
5/20/2014Leonard BellCEOSell70,000$155.96$10,917,200.001,032,331View SEC Filing  
5/14/2014Martin MackayEVPSell3,574$160.85$574,877.9024,426View SEC Filing  
5/13/2014Alvin ParvenDirectorSell12,276$160.78$1,973,735.284,840View SEC Filing  
4/29/2014Leonard BellCEOSell70,000$156.20$10,934,000.001,032,331View SEC Filing  
2/10/2014Stephen SquintoEVPSell7,055$158.04$1,114,972.20101,308View SEC Filing  
2/7/2014David HallalEVPSell1,620$155.57$252,023.40113,965View SEC Filing  
2/7/2014Frank WrightSVPSell1,098$155.57$170,815.8619,670View SEC Filing  
2/7/2014Joseph MadriDirectorSell30,000$159.00$4,770,000.00179,217View SEC Filing  
2/7/2014Leonard BellCEOSell4,620$155.56$718,687.20986,696View SEC Filing  
2/4/2014Leonard BellCEOSell11,790$154.50$1,821,555.00963,276View SEC Filing  
2/4/2014Stephen SquintoEVPSell36,989$155.12$5,737,733.6894,818View SEC Filing  
2/4/2014Vikas SinhaCFOSell3,552$154.47$548,677.44129,775View SEC Filing  
1/29/2014Leonard BellCEOSell2,660$133.81$355,934.60975,066View SEC Filing  
1/29/2014Stephen SquintoEVPSell1,118$133.31$149,040.58103,068View SEC Filing  
1/22/2014Leonard BellCEOSell156,436$140.80$22,026,188.80977,726View SEC Filing  
1/10/2014Leonard BellCEOSell19,155$134.98$2,585,541.901,031,957View SEC Filing  
12/19/2013Leonard BellCEOSell175,000$126.38$22,116,500.001,031,957View SEC Filing  
10/28/2013Stephen P SquintoEVPSell41,037$124.06$5,091,050.22View SEC Filing  
10/28/2013Vikas SinhaCFOSell50,000$122.97$6,148,500.00View SEC Filing  
9/16/2013Joseph MadriDirectorSell30,000$115.00$3,450,000.00179,217View SEC Filing  
9/16/2013Leonard BellCEOSell3,500$115.00$402,500.001,026,293View SEC Filing  
9/13/2013Stephen SquintoEVPSell1,000$114.37$114,370.00View SEC Filing  
9/4/2013Leonard BellCEOSell1,850$110.07$203,629.50View SEC Filing  
9/3/2013Leonard BellCEOSell33,150$110.19$3,652,798.501,003,519View SEC Filing  
8/30/2013Clare CarmichaelSVPSell1,237$107.58$133,076.469,463View SEC Filing  
8/16/2013Leonard BellCEOSell140,000$106.08$14,851,200.001,036,669View SEC Filing  
8/5/2013Leonard BellCEOSell2,919$116.87$341,143.531,176,669View SEC Filing  
8/2/2013Stephen P SquintoEVPSell14,125$115.33$1,629,036.25View SEC Filing  
7/30/2013Leonard BellCEOSell212,737$114.62$24,383,914.94View SEC Filing  
7/30/2013Stephen P SquintoEVPSell1,120$110.86$124,163.20View SEC Filing  
7/12/2013David HallalEVPSell50,000$120.00$6,000,000.00View SEC Filing  
7/1/2013Stephen P SquintoEVPSell44,125$94.97$4,190,551.25View SEC Filing  
5/22/2013R Douglas NorbyDirectorSell40,000$102.77$4,110,800.00View SEC Filing  
5/20/2013William R KellerDirectorSell9,770$103.00$1,006,310.00View SEC Filing  
5/14/2013Leonard BellCEOSell31,113$105.74$3,289,888.62View SEC Filing  
5/13/2013Leonard BellCEOSell41,220$100.85$4,157,037.00View SEC Filing  
4/10/2013Leonard BellCEOSell26,700$100.24$2,676,408.00View SEC Filing  
2/4/2013Leonard BellCEOSell11,880$96.27$1,143,687.60View SEC Filing  
2/4/2013Stephen P SquintoEVPSell2,572$95.68$246,088.96View SEC Filing  
2/4/2013Vikas SinhaCFOSell3,483$95.81$333,706.23View SEC Filing  
1/15/2013Leonard BellCEOSell35,000$98.58$3,450,300.00View SEC Filing  
10/31/2012Patrice CoissacSVPSell84,764$91.16$7,727,086.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alexion Pharmaceuticals (NASDAQ ALXN) News Headlines

Source:
DateHeadline
Alexion (ALXN) Tops Q1 Earnings and Sales Beat EstimatesAlexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates
www.zacks.com - April 26 at 8:15 AM
Alexion Pharmaceuticals beats by $0.18, beats on revenueAlexion Pharmaceuticals beats by $0.18, beats on revenue
seekingalpha.com - April 26 at 8:15 AM
Alexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch StudyAlexion Reports First Quarter 2018 Results and Positive Topline Data from ALXN1210 Phase 3 PNH Switch Study
finance.yahoo.com - April 26 at 8:15 AM
Alexion: 1Q Earnings SnapshotAlexion: 1Q Earnings Snapshot
finance.yahoo.com - April 26 at 8:15 AM
$1.48 EPS Expected for Alexion Pharmaceuticals (ALXN) This Quarter$1.48 EPS Expected for Alexion Pharmaceuticals (ALXN) This Quarter
www.americanbankingnews.com - April 25 at 5:10 PM
[$$] New Biotech Grabs Series A for Rare Disease Treatments[$$] New Biotech Grabs Series A for Rare Disease Treatments
finance.yahoo.com - April 25 at 8:19 AM
Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings SeasonWhy Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season
finance.yahoo.com - April 24 at 5:36 PM
Alexion Pharmaceuticals (ALXN) Buy Rating Reaffirmed at Raymond JamesAlexion Pharmaceuticals' (ALXN) Buy Rating Reaffirmed at Raymond James
www.americanbankingnews.com - April 24 at 8:20 AM
Alexion Pharmas (ALXN) 4/26 Earnings Will Focus On Brazil - GoldmanAlexion Pharma's (ALXN) 4/26 Earnings Will Focus On Brazil - Goldman
www.streetinsider.com - April 24 at 8:18 AM
Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy? April 23, 2018Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy? April 23, 2018
www.zacks.com - April 24 at 8:18 AM
Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - April 23 at 8:14 AM
BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In BrazilBRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil
www.reuters.com - April 22 at 8:16 AM
Alexion Pharma (ALXN) Defended at LeerinkAlexion Pharma (ALXN) Defended at Leerink
www.streetinsider.com - April 22 at 8:16 AM
Alexion Pharmaceuticals (ALXN) Buy Rating Reiterated at UBSAlexion Pharmaceuticals' (ALXN) Buy Rating Reiterated at UBS
www.americanbankingnews.com - April 20 at 9:46 PM
UBS Reiterates Buy Rating for Alexion Pharmaceuticals (ALXN)UBS Reiterates Buy Rating for Alexion Pharmaceuticals (ALXN)
www.americanbankingnews.com - April 20 at 5:52 PM
Implications from Soliris patent ruling in Brazil likely immaterial says AlexionImplications from Soliris patent ruling in Brazil likely immaterial says Alexion
seekingalpha.com - April 20 at 5:22 PM
Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris (Eculizumab)Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris (Eculizumab)
www.finanznachrichten.de - April 20 at 5:22 PM
Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris® (Eculizumab)Alexion Provides Statement on Superior Court of Justice (STJ) Decision in Brazil Involving Soliris® (Eculizumab)
finance.yahoo.com - April 20 at 5:22 PM
Alexion Slips On Reports Brazil Will Allow Copycats Of Blockbuster SolirisAlexion Slips On Reports Brazil Will Allow Copycats Of Blockbuster Soliris
finance.yahoo.com - April 20 at 5:22 PM
Alexion Pharmaceuticals (ALXN) Receives Average Rating of "Buy" from AnalystsAlexion Pharmaceuticals (ALXN) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 20 at 1:26 AM
Alexion Pharmaceuticals (ALXN) Upgraded at Zacks Investment ResearchAlexion Pharmaceuticals (ALXN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 19 at 11:46 AM
Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, Alder Biopharma, and Alexion PharmaTechnical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, Alder Biopharma, and Alexion Pharma
www.bizjournals.com - April 19 at 8:14 AM
Q1 2018 EPS Estimates for Alexion Pharmaceuticals Boosted by Analyst (ALXN)Q1 2018 EPS Estimates for Alexion Pharmaceuticals Boosted by Analyst (ALXN)
www.americanbankingnews.com - April 19 at 6:28 AM
Ra Pharmaceuticals Appoints John C. King as Chief Commercial OfficerRa Pharmaceuticals Appoints John C. King as Chief Commercial Officer
www.businesswire.com - April 18 at 8:15 AM
B.Riley/FBR Downgrades Alexion Pharmaceuticals (ALXN) to Neutral Following Acquisition of Wilson TherapeuticsB.Riley/FBR Downgrades Alexion Pharmaceuticals (ALXN) to Neutral Following Acquisition of Wilson Therapeutics
www.streetinsider.com - April 18 at 8:15 AM
Alexion Pharmaceuticals (ALXN) Scheduled to Post Earnings on WednesdayAlexion Pharmaceuticals (ALXN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 18 at 3:28 AM
Alexion Pharmaceuticals (ALXN) Upgraded at BidaskClubAlexion Pharmaceuticals (ALXN) Upgraded at BidaskClub
www.americanbankingnews.com - April 16 at 12:03 PM
Alexion Pharmaceuticals Forecasted to Earn Q1 2018 Earnings of $1.25 Per Share (ALXN)Alexion Pharmaceuticals Forecasted to Earn Q1 2018 Earnings of $1.25 Per Share (ALXN)
www.americanbankingnews.com - April 16 at 1:44 AM
Alexion Pharmaceuticals (ALXN) Upgraded to "Strong-Buy" at Zacks Investment ResearchAlexion Pharmaceuticals (ALXN) Upgraded to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - April 14 at 10:19 AM
Alexion Spruces Up Its Pipeline With $855 Million Buy Of Rare Disease Drug MakerAlexion Spruces Up Its Pipeline With $855 Million Buy Of Rare Disease Drug Maker
seekingalpha.com - April 13 at 8:18 AM
Blog Exposure - Alexion Pharma to Acquire Swedish Biotech Wilson TherapeuticsBlog Exposure - Alexion Pharma to Acquire Swedish Biotech Wilson Therapeutics
finance.yahoo.com - April 13 at 8:18 AM
Alexion Pharmaceuticals (ALXN) PT Raised to $165.00 at NomuraAlexion Pharmaceuticals (ALXN) PT Raised to $165.00 at Nomura
www.americanbankingnews.com - April 12 at 10:46 AM
Your Daily Pharma Scoop: Paratek Update, Alexion Acquisition, Arrowhead DataYour Daily Pharma Scoop: Paratek Update, Alexion Acquisition, Arrowhead Data
seekingalpha.com - April 12 at 8:33 AM
Alexion Joins The Biotech M&A BonanzaAlexion Joins The Biotech M&A Bonanza
seekingalpha.com - April 12 at 8:33 AM
Alexion Pharmaceuticals (ALXN) PT Raised to $113 at Jefferies on Plan to Acqurie WTX101Alexion Pharmaceuticals (ALXN) PT Raised to $113 at Jefferies on Plan to Acqurie WTX101
www.streetinsider.com - April 11 at 5:33 PM
Why Alexion Pharmaceuticals Inc (NASDAQ:ALXN) May Not Be As Efficient As Its IndustryWhy Alexion Pharmaceuticals Inc (NASDAQ:ALXN) May Not Be As Efficient As Its Industry
finance.yahoo.com - April 11 at 5:33 PM
How Alexion Could Diversify From Its Cash Cow To Battle Valeant, TevaHow Alexion Could Diversify From Its Cash Cow To Battle Valeant, Teva
finance.yahoo.com - April 11 at 5:33 PM
Alexion Pharma To Buy Swedens Wilson Therapeutics For $855 Mln In CashAlexion Pharma To Buy Sweden's Wilson Therapeutics For $855 Mln In Cash
www.nasdaq.com - April 11 at 8:29 AM
Biotech M&A rolls on as Alexion snaps up Wilson for $855 millionBiotech M&A rolls on as Alexion snaps up Wilson for $855 million
www.reuters.com - April 11 at 8:29 AM
Alexion Pharma (ALXN) Agrees to Acquire Wilson Therapeutics for $855MAlexion Pharma (ALXN) Agrees to Acquire Wilson Therapeutics for $855M
www.streetinsider.com - April 11 at 8:29 AM
Alexion to Acquire Wilson TherapeuticsAlexion to Acquire Wilson Therapeutics
finance.yahoo.com - April 11 at 8:29 AM
Alexion to buy Swedish biotech Wilson Therapeutics for $855 mlnAlexion to buy Swedish biotech Wilson Therapeutics for $855 mln
finance.yahoo.com - April 11 at 8:29 AM
[$$] Alexion Makes Bid for Swedens Wilson Therapeutics[$$] Alexion Makes Bid for Sweden's Wilson Therapeutics
finance.yahoo.com - April 11 at 8:29 AM
Biotech M&A rolls on as Alexion snaps up Wilson for $855 mlnBiotech M&A rolls on as Alexion snaps up Wilson for $855 mln
finance.yahoo.com - April 11 at 8:29 AM
BidaskClub Lowers Alexion Pharmaceuticals (ALXN) to BuyBidaskClub Lowers Alexion Pharmaceuticals (ALXN) to Buy
www.americanbankingnews.com - April 10 at 4:29 PM
Alexion Pharmaceuticals (ALXN) Upgraded by Zacks Investment Research to "Hold"Alexion Pharmaceuticals (ALXN) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 10 at 12:01 PM
$919.03 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter$919.03 Million in Sales Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter
www.americanbankingnews.com - April 10 at 2:36 AM
Alexion Pharmaceuticals, Inc. Is Researching a TurnaroundAlexion Pharmaceuticals, Inc. Is Researching a Turnaround
investorplace.com - April 9 at 1:48 PM
Alexion Pharmaceuticals (ALXN) Stock Rating Upgraded by JPMorgan ChaseAlexion Pharmaceuticals (ALXN) Stock Rating Upgraded by JPMorgan Chase
www.americanbankingnews.com - April 9 at 1:19 PM
 Analysts Anticipate Alexion Pharmaceuticals, Inc. (ALXN) to Announce $1.48 Earnings Per Share Analysts Anticipate Alexion Pharmaceuticals, Inc. (ALXN) to Announce $1.48 Earnings Per Share
www.americanbankingnews.com - April 8 at 7:15 PM

SEC Filings

Alexion Pharmaceuticals (NASDAQ:ALXN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alexion Pharmaceuticals (NASDAQ:ALXN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alexion Pharmaceuticals (NASDAQ ALXN) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.